3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
93
Lung Neoplasms
35
Meningeal Carcinomatosis
11
Neoplasms
10
Neoplasm Metastasis
8
Colorectal Neoplasms
6
Adenocarcinoma of Lung
6
Parkinson Disease 4, Autosomal Dominant Lewy Body
4
Mesothelioma, Malignant
4
Non-squamous Non-small Cell Lung Cancer
3
NSCLC
3
Mesothelioma
3
Carcinoma
3
Advanced Solid Tumors
3
Pancreatic Neoplasms
2
Non Squamous Non Small Cell Lung Cancer
2
Neoplasms by Site
2
Neoplasms by Histologic Type
2
Endometrial Neoplasms
2
Carcinoma, Bronchogenic
2
Bronchial Neoplasms
2
Breast Neoplasms
2
Vaccinia
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Thoracic Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumors
1
Small Cell Lung Carcinoma
1
Sexual Dysfunction, Physiological
1
Interventions
pembrolizumab
1
Pemetrexed
1
Control Groups
1
Cisplatin
1
Carboplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Pathologic Processes
×
Pemetrexed
×
Clear all
NCT06119581
2026-05-19
SUNRAY-01
Eli Lilly and Company
Phase 3
Recruiting
1,264 enrolled